{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=NSAA", "query": { "intervention": "NSAA" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 8, "total_pages": 1, "next_page_url": null, "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-03T09:23:55.867Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT05881408", "title": "A Gene Transfer Therapy Study to Evaluate the Safety and Efficacy of Delandistrogene Moxeparvovec (SRP-9001) in Non-Ambulatory and Ambulatory Participants With Duchenne Muscular Dystrophy (DMD)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Duchenne Muscular Dystrophy" ], "interventions": [ { "name": "delandistrogene moxeparvovec", "type": "GENETIC" }, { "name": "placebo", "type": "GENETIC" } ], "intervention_types": [ "GENETIC" ], "sponsor": "Sarepta Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "MALE", "summary": "Male only" }, "enrollment_count": 148, "start_date": "2023-05-31", "completion_date": "2028-06-30", "has_results": false, "last_update_posted_date": "2026-05-22", "last_synced_at": "2026-09-03T09:23:55.867Z", "location_count": 14, "location_summary": "Little Rock, Arkansas • Palo Alto, California • Sacramento, California + 11 more", "locations": [ { "city": "Little Rock", "state": "Arkansas" }, { "city": "Palo Alto", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "Gainesville", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT05881408" }, { "nct_id": "NCT02446405", "title": "Enzalutamide in First Line Androgen Deprivation Therapy for Metastatic Prostate Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Prostatic Neoplasms" ], "interventions": [ { "name": "Enzalutamide", "type": "DRUG" }, { "name": "NSAA", "type": "DRUG" }, { "name": "LHRHA or Surgical Castration", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Sydney", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 1125, "start_date": "2014-03", "completion_date": "2027-06-30", "has_results": false, "last_update_posted_date": "2025-02-06", "last_synced_at": "2026-09-03T09:23:55.867Z", "location_count": 1, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT02446405" }, { "nct_id": "NCT03020030", "title": "Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Children and Adolescents", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Acute Lymphoblastic Leukemia, Pediatric" ], "interventions": [ { "name": "Pegaspargase", "type": "DRUG" }, { "name": "Erwinia asparaginase", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "CYTARABINE", "type": "DRUG" }, { "name": "DASATINIB", "type": "DRUG" }, { "name": "DEXAMETHASONE", "type": "DRUG" }, { "name": "Dexrazoxane", "type": "DRUG" }, { "name": "Doxorubicin", "type": "DRUG" }, { "name": "ETOPOSIDE", "type": "DRUG" }, { "name": "HYDROCORTISONE", "type": "DRUG" }, { "name": "LEUCOVORIN CALCIUM", "type": "DRUG" }, { "name": "MERCAPTOPURINE", "type": "DRUG" }, { "name": "METHOTREXATE", "type": "DRUG" }, { "name": "NELARABINE", "type": "DRUG" }, { "name": "Vincristine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Dana-Farber Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Year", "maximum_age": "21 Years", "sex": "ALL", "summary": "1 Year to 21 Years" }, "enrollment_count": 560, "start_date": "2017-03-03", "completion_date": "2034-11", "has_results": false, "last_update_posted_date": "2026-07-16", "last_synced_at": "2026-09-03T09:23:55.867Z", "location_count": 7, "location_summary": "Boston, Massachusetts • New Brunswick, New Jersey • Buffalo, New York + 3 more", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "New Brunswick", "state": "New Jersey" }, { "city": "Buffalo", "state": "New York" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT03020030" }, { "nct_id": "NCT06054971", "title": "NSAA NON-Interventional Study Protocol", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Duchenne Muscular Dystrophy" ], "interventions": [ { "name": "Remote Administration of NSAA", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "Red Nucleus Enterprise Solutions, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "4 Years", "maximum_age": "12 Years", "sex": "ALL", "summary": "4 Years to 12 Years" }, "enrollment_count": 31, "start_date": "2023-10-02", "completion_date": "2025-03-13", "has_results": false, "last_update_posted_date": "2025-03-21", "last_synced_at": "2026-09-03T09:23:55.867Z", "location_count": 1, "location_summary": "Malvern, Pennsylvania", "locations": [ { "city": "Malvern", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT06054971" }, { "nct_id": "NCT02446444", "title": "Enzalutamide in Androgen Deprivation Therapy With Radiation Therapy for High Risk, Clinically Localised, Prostate Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Prostatic Neoplasms" ], "interventions": [ { "name": "Enzalutamide", "type": "DRUG" }, { "name": "Conventional NSAA", "type": "DRUG" }, { "name": "LHRHA", "type": "DRUG" }, { "name": "External Beam Radiotherapy (78 Gy in 39 fractions or 46 Gy in 23 fractions plus brachytherapy boost)", "type": "RADIATION" } ], "intervention_types": [ "DRUG", "RADIATION" ], "sponsor": "University of Sydney", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 802, "start_date": "2014-03", "completion_date": "2026-06", "has_results": false, "last_update_posted_date": "2026-05-06", "last_synced_at": "2026-09-03T09:23:55.867Z", "location_count": 2, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT02446444" }, { "nct_id": "NCT03769116", "title": "A Randomized, Double-blind, Placebo-controlled Study of Delandistrogene Moxeparvovec (SRP-9001) for Duchenne Muscular Dystrophy (DMD)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Muscular Dystrophy, Duchenne" ], "interventions": [ { "name": "delandistrogene moxeparvovec", "type": "GENETIC" }, { "name": "placebo", "type": "GENETIC" } ], "intervention_types": [ "GENETIC" ], "sponsor": "Sarepta Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "4 Years", "maximum_age": "7 Years", "sex": "MALE", "summary": "4 Years to 7 Years · Male only" }, "enrollment_count": 41, "start_date": "2018-12-05", "completion_date": "2023-08-16", "has_results": true, "last_update_posted_date": "2024-11-14", "last_synced_at": "2026-09-03T09:23:55.867Z", "location_count": 2, "location_summary": "Los Angeles, California • Columbus, Ohio", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Columbus", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT03769116" }, { "nct_id": "NCT01643408", "title": "A Study of Erwinaze Administered Intravenously in Patients Who Had an Allergy to Frontline Asparaginase Therapy", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Acute Lymphoblastic Leukemia", "Lymphoblastic Lymphoma" ], "interventions": [ { "name": "asparaginase Erwinia chrysanthemi", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Jazz Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Year", "maximum_age": "30 Years", "sex": "ALL", "summary": "1 Year to 30 Years" }, "enrollment_count": 30, "start_date": "2012-11", "completion_date": "2013-12", "has_results": true, "last_update_posted_date": "2021-06-23", "last_synced_at": "2026-09-03T09:23:55.867Z", "location_count": 18, "location_summary": "Los Angeles, California • Orange County, California • Palo Alto, California + 15 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Orange County", "state": "California" }, { "city": "Palo Alto", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "St. Petersburg", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT01643408" }, { "nct_id": "NCT05096221", "title": "A Gene Transfer Therapy Study to Evaluate the Safety and Efficacy of Delandistrogene Moxeparvovec (SRP-9001) in Participants With Duchenne Muscular Dystrophy (DMD)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Duchenne Muscular Dystrophy" ], "interventions": [ { "name": "delandistrogene moxeparvovec", "type": "GENETIC" }, { "name": "placebo", "type": "GENETIC" } ], "intervention_types": [ "GENETIC" ], "sponsor": "Sarepta Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "4 Years", "maximum_age": "7 Years", "sex": "MALE", "summary": "4 Years to 7 Years · Male only" }, "enrollment_count": 126, "start_date": "2021-10-27", "completion_date": "2024-10-25", "has_results": true, "last_update_posted_date": "2025-07-08", "last_synced_at": "2026-09-03T09:23:55.867Z", "location_count": 23, "location_summary": "Little Rock, Arkansas • La Jolla, California • Los Angeles, California + 20 more", "locations": [ { "city": "Little Rock", "state": "Arkansas" }, { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Palo Alto", "state": "California" }, { "city": "Sacramento", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05096221" } ] }